Pharmacotherapy of multiple sclerosis: the PROOF trial.
BACKGROUND
Currently approved disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) include two different interferon beta-1a (IFNB-1a) preparations: subcutaneous IFNB-1a (Rebif) 44 microg three times weekly and intramuscular IFNB-1a (Avonex) 30 microg once weekly.


OBJECTIVE
This evaluation is of the Prospective and Retrospective Long-Term Observational Study of Avonex and Rebif (PROOF), which intended to compare relative efficacy and tolerability of the two INFB-1a products.


METHODS
PROOF was analyzed in light of previous head-to-head studies comparing high- and low-frequency IFNB therapies.


CONCLUSIONS
Several limitations, including a retrospective-prospective design, retrospective assessment of variables without predefined criteria, limited prospective evaluation, and inadequate sample size, necessitate careful interpretation of their Results. Ultimately, the question of long-term efficacy of high- versus low-frequency INFB therapies remains unanswered.
Boster
Aaron
A
Racke
Michael K
MK
D006801:Humans; D007279:Injections, Subcutaneous; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011446:Prospective Studies; D011994:Recombinant Proteins; D012189:Retrospective Studies
D007370:Interferon Type I; D011994:Recombinant Proteins